For cost-effective, streamlined, targeted next-generation sequencing (NGS) of specific genetic diseases or conditions, Illumina offers TruSight sequencing panels. Designed with recognized healthcare experts at leading institutions, TruSight panels comprise oligo probes targeting genes and regions thought to be relevant for particular diseases or conditions.
Each TruSight sequencing panel offers:
Comprehensive panel detects single-nucleotide variants (SNVs), amplifications, and fusions that contribute to solid tumor progression.
The TruSight Oncology UMI Reagents and UMI Error Correction App reduce error rates in samples to ≤0.007%, enabling the detection of low frequency variants.
Targeting 507 fusion associated genes in cancer; detects known and novel fusion gene partners.
Comprehensive panels targeting disease-associated regions of the exome with high analytical sensitivity and specificity.
Accurate, unambiguous, phase-resolved HLA typing in a single assay.
Targeting 1385 oncology genes for gene expression, variant and fusion detection in all RNA sample types including FFPE.
Uses expert-defined content to identify somatic mutations in myeloid malignancies.
Targeting genes previously linked to a predisposition towards cancer.
Focused panel assesses common somatic variants in solid tumors.
Focusing on identifying inherited cardiac conditions.
Focusing on severe, recessive pediatric onset diseases.
A highly multiplexed polymerase chain reaction (PCR)-based workflow for use with targets ranging from a few to hundreds of genes in a single run.
Illumina offers a broad portfolio of cancer-focused products across multiple application areas.
Discontinued TruSight products and recommended replacements are shown below: